Preclinical
October 16, 2023
World ADC San Diego
ZW251 – A novel glypican-3 targeting ADC bearing a topoisomerase I inhibitor payload
Laurence Madera
Zanidatamab Zovodotin
October 13, 2023
AACR-EORTC-NCI
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers
Oh et al.
Preclinical
October 12, 2023
AACR-EORTC-NCI
Refining our understanding of ADCs: Drug development insights from 40 years of data
Raffaele Colombo
Preclinical
October 10, 2023
Festival of Biologics
TOPO1i ADC Platform From Concept to Pipeline Application
Mark Petersen
Preclinical
October 2, 2023
World Bispecific Summit
Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
Nina Weisser
Preclinical
June 12, 2023
Journal of Medicinal Chemistry
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
Petersen et al.
Zanidatamab
June 2, 2023
ASCO
Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)
Pant et al.
Zanidatamab
June 4, 2023
ASCO
Zanidatamab, a HER2-targeted Bispecific Antibody, in Combination With Docetaxel as First-line Therapy for Patients With Advanced HER2-positive Breast Cancer: Updated Results From a Phase 1b/2 Study
Wang et al.
Zanidatamab
June 2, 2023
Lancet Oncology
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Harding et al.
Preclinical
June 2, 2023
Bioorganic & Medicinal Chemistry Letters
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Brant et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
May 19, 2023
PEGS
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Piscitelli et al.
